Accepted at 9:18 p.m. Oct, 31, 2023 by Alex
Author: ThomasHollan
Related Note: 1496035182976
Rationale for change

Added additional info from amboss about Dupilumab (that it is a IL-4r inhibitor), in the extra feild


https://next.amboss.com/us/article/4p03pS?utm_source=anki&utm_medium=anki&utm_campaign=anki&utm_term=dupilumab&guid=JA1%253Fiz%2560b%2FD&aid=d106d510-f3ad-41a1-8149-03104d45410f&uid=Z1fcZ2Ob0#Zbe6dd765da918cc9b211a4fd56ab8aa1

Extra Extra
Text
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Empty field
Sketchy
Empty field
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step1_v12::#OME_banner #AK_Step1_v12::#FirstAid::04_Pathology::03_Neoplasia::05_Immune_checkpoint_interactions::*Dupilumab #AK_Step1_v12::^Other::^EXPN #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::02_Blood_Cells::04_Basophil #AK_Step1_v12::#SketchyPharm::Immunology-&-Biochemistry-Pharmacology::Immuno-suppressives::General-Immunotherapy #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#FirstAid::02_Immunology::04_Immunosuppressants::03_Therapeutic_antibodies::01_Autoimmune_disease_therapy::*Dupilumab #AK_Step1_v12::#Bootcamp::Dermatology::03_Inflammatory_Diseases_of_the_Skin::03_Atopic_and_Allergic_Diseases #AK_Step1_v12::#AMBOSS::7B04Xi #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::02_Blood_Cells::03_Mast_Cell #AK_Step1_v12::#Low/HighYield::4-LowerYield